Ips Heart Inc. has been awarded orphan drug designation by the FDA for its GIVI-MPC stem cell therapy for Becker muscular dystrophy. GIVI-MPC has the unique ability to create new muscle with full ...
Dyne Therapeutics' DYNE-101 shows promising Phase 1/2 results for myotonic dystrophy type 1, with plans for Accelerated ...
Dyne Therapeutics (NASDAQ:DYN) reported clinical data from its ongoing Phase 1/2 trial of DYNE-101 in patients with myotonic dystrophy type 1. Shares down about 22% in early trade. DYNE-101 continued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback